Clinical Trials Directory

Trials / Completed

CompletedNCT05122442

Multicenter, Non-interventional Study, Describing Patients With Inherited Retinal Disease (IRD) in France

Status
Completed
Phase
Study type
Observational
Enrollment
998 (actual)
Sponsor
University Hospital, Strasbourg, France · Academic / Other
Sex
All
Age
6 Years
Healthy volunteers
Not accepted

Summary

Genetic diagnostic testing becomes increasingly important for enhancing our understanding of the disease notably the genetics and providing the best care to the patients, and several initiatives seek to gather more data in order to better understand and treat those diseases. Within this context, Novartis and SENSGENE/Strasbourg University Hospitals (HUS) want to set up, through a research collaboration, a non-interventional study in France to better understand the epidemiology of IRDs, particularly the distribution of pathogenic variants in patients. This study aims to serve as a starter study to implement an IRD national registry led by SENSGENE/Strasbourg University Hospitals (HUS). The data collected might also be used to populate global European registries. The primary objective has been defined in a sufficient broad way to address this perspective of registries. As IRDs can present from birth to late middle age, this study will include both children and adult patients regardless of age, sex, and the type of IRD.

Conditions

Interventions

TypeNameDescription
OTHERPatients with inherited retinal diseasePatients with inherited retinal disease

Timeline

Start date
2021-11-30
Primary completion
2023-12-01
Completion
2023-12-01
First posted
2021-11-16
Last updated
2026-01-27
Results posted
2026-01-27

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05122442. Inclusion in this directory is not an endorsement.